TCR Based Therapeutics: A Deep Dive in Targets for Cancer IO

When:  Dec 7, 2022 from 14:00 to 16:00 (CT)
This webinar, the eighth of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind therapies involving T cell receptors. Basic, clinical and translational researchers in academia and industry and members of the investment community are the target audience of this series.

Moderators:
  • Harlan Robins, PhD – Adaptive Biotechnologies Corporation
  • Harpreet Singh, PhD – Immatics Biotechnologies GmbH
Faculty:
  • TBD

Learn more about the 2022 Targets for Cancer IO: A Deep Dive Series here!

Targets for Cancer IO: A Deep Dive Series is supported, in part, by educational grants from Genmab, US, Inc. and Merck & Co., Inc. (as of 6/6/2022).

#TargetsforCancerImmunotherapyADeepDiveSeminarSeries #NoCEOffered #Industry #Researcher #2022